Han Hui, Dai Daopeng, Wang Wencheng, Zhu Jinzhou, Zhu Zhengbin, Lu Lin, Zhang Ruiyan
Department of Cardiology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, PR China.
Institute of Cardiovascular Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, PR China.
J Interv Med. 2019 Jun 27;2(1):16-20. doi: 10.1016/j.jimed.2019.05.005. eCollection 2019 Feb.
The purpose of this study was to investigate the relationship between serum levels of lipoprotein lipase (LPL), hepatic lipase (HL), and endothelial lipase (EL) and the progression of coronary artery disease (CAD).
According to the inclusion criteria, exclusion criteria, diagnostic criteria, angiography results, and the random matching scheme, the enrolled patients were divided into the following two groups: the progression-free group (n = 47) and the progression group (n = 15). The baseline characteristics and various biochemical parameters were obtained from the medical records and medical history. Serum LPL, HL, and EL levels were detected by ELISA. The correlation between serum LPL, HL, and EL levels and coronary lesions was statistically analyzed with SPSS software.
Significant differences were observed in serum levels of HL and EL between the progression-free group and the progression group (HL, 75.5 ± 39.2 ng/mL vs. 125.1 ± 42.1 ng/mL, P < 0.05; EL, 139.2 ± 59.6 pg/mL vs. 175.1 ± 40.1 pg/mL, P < 0.05), while the difference in the LPL level was not significant (P > 0.05). Receiver operating characteristic curve (ROC) analysis showed that the area under the curve (AUC) values of LPL, HL, and EL were 0.506 (95% CI: 0.369-0.642, P = 0.9470), 0.792 (95% CI: 0.664-0.888, P < 0.0001), and 0.693 (95% CI: 0.553-0.811, P = 0.0095), respectively. Additionally, logistic regression analysis showed that the serum level of HL was an independent risk factor for coronary artery lesion progression.
Serum levels of EL and HL, but not the serum level of LPL, were positively correlated with the progression of CAD. The serum level of HL was an independent risk factor for the progression of CAD, while the erum level of EL or LPL was not an independent risk factor for the progression of CAD. For the diagnosis of CAD progression, the serum level of HL was better than the erum level of EL or LPL.
本研究旨在探讨血清脂蛋白脂肪酶(LPL)、肝脂肪酶(HL)和内皮脂肪酶(EL)水平与冠状动脉疾病(CAD)进展之间的关系。
根据纳入标准、排除标准、诊断标准、血管造影结果及随机匹配方案,将入选患者分为以下两组:无进展组(n = 47)和进展组(n = 15)。从病历和病史中获取基线特征及各项生化参数。采用酶联免疫吸附测定法(ELISA)检测血清LPL、HL和EL水平。使用SPSS软件对血清LPL、HL和EL水平与冠状动脉病变之间的相关性进行统计学分析。
无进展组与进展组之间HL和EL的血清水平存在显著差异(HL,75.5±39.2 ng/mL对125.1±42.1 ng/mL,P < 0.05;EL,139.2±59.6 pg/mL对175.1±40.1 pg/mL,P < 0.05),而LPL水平差异不显著(P > 0.05)。受试者工作特征曲线(ROC)分析显示,LPL、HL和EL的曲线下面积(AUC)值分别为0.506(95%可信区间:0.369 - 0.642,P = 0.9470)、0.792(95%可信区间:0.664 - 0.888,P < 0.0001)和0.693(95%可信区间:0.553 - 0.811,P = 0.0095)。此外,逻辑回归分析显示,HL的血清水平是冠状动脉病变进展的独立危险因素。
EL和HL的血清水平与CAD进展呈正相关,而LPL的血清水平与CAD进展无关。HL的血清水平是CAD进展的独立危险因素,而EL或LPL的血清水平不是CAD进展的独立危险因素。对于CAD进展的诊断,HL的血清水平优于EL或LPL的血清水平。